Molecular Imaging and Diagnostics in Alzheimer’s Patients
The second subproject deals with diagnostic technology for early detection of ageing and neurodegenerative diseases. The scarcity of treatments for neurodegenerative disease also has to do with the inefficiency of early detection diagnostic instruments. However, this picture is starting to change: an early diagnosis means that experimental drugs can be used in the initial stages of a disease and thus potentially alter its course. Nowadays, with the in-depth examination of diagnostic tools, and the possibility of combining results with genetic testing and the proteomic analysis of cerebrospinal fluid, make it so that clinical experimentations can start early with demonstrable results in little amounts of time. The main characteristic of neurodegenerative diseases is, in fact, the slow clinical course which creates difficulties in clinical experimentation. A recent multicenter study by the American NIH, which made use of the latest imaging technology, evidenced a slowing down in the clinical course in Alzheimer’s patients who were diagnosed early. Therefore, molecular and modern imaging technologies may finally lead to innovative treatments for this type of pathology. The second subproject is thus dedicated to imaging technologies and clinical staging of patients with neurodegenerative pathologies.